Primary Sclerosing Cholangitis clinical trials at UC Davis
2 research studies open to eligible people
PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
open to eligible people ages 18-75
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
Sacramento, California and other locations
Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 12 years and up
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Sacramento, California and other locations
Our lead scientists for Primary Sclerosing Cholangitis research studies include Christopher Bowlus, MD.
Last updated: